Seres Therapeutics, Inc.
MCRB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $48 | $45 | $59 | $31 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $1 | $1 | $4 | $5 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $2 | $3 | $3 |
| Total Curr. Assets | $52 | $49 | $66 | $39 |
| Property Plant & Equip (Net) | $83 | $86 | $89 | $92 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $9 | $9 | $9 | $9 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $92 | $95 | $98 | $101 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $143 | $144 | $164 | $140 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $2 | $4 |
| Short-Term Debt | $10 | $9 | $9 | $9 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $11 | $19 | $20 | $28 |
| Total Curr. Liab. | $22 | $31 | $31 | $41 |
| LT Debt | $75 | $78 | $80 | $83 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $2 | $2 | $2 | $2 |
| Total NC Liab. | $77 | $80 | $82 | $85 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $75 | $87 | $90 | $92 |
| Total Liabilities | $100 | $111 | $114 | $126 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$957 | -$965 | -$945 | -$978 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,001 | $998 | $996 | $992 |
| Total Equity | $44 | $33 | $50 | $14 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $143 | $144 | $164 | $140 |
| Net Debt | $38 | $42 | $31 | $61 |